Page 80 - Biomarkers for risk stratification and guidance in heart failure
P. 80
CHAPTER 4
Which heart failure patients profit from natriuretic peptide- guided therapy? A meta-analysis from individual patient data of randomized trials
Hans-Peter Brunner-La Rocca1*, Luc Eurlings1, A. Mark Richards2,3, James L. Januzzi4, Matthias E. Pfisterer5, Ulf Dahlström6, Yigal M. Pinto7, Patric Karlström8, Hans Erntell9, Rudolf Berger10, Hans Persson9, Christopher M. O’Connor11, Deddo Moertl12, Hanna K. Gaggin4, Christopher M. Frampton2, M. Gary Nicholls2, and Richard W. Troughton2
1 Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands; 2 Department of Medicine, University of Otago Christchurch, Christchurch Hospital, Christchurch, New Zealand; 3 National University Heart Centre Singapore, Singapore; 4 Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 5 Department of Cardiology, University Hospital Basel, Basel, Switzerland; 6 Department of Cardiology and Department of Medical and Health Sciences, Linkoping University, Department of Cardiology, Linkoping, Sweden; 7 Academic Medical Centre, Amsterdam, the Netherlands; 8 Division of Cardiology, Department of Medicine, County Hospital Ryhov, Jonkoping, Sweden; 9 Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden; 10 Department of Cardiology, Medical University of Vienna, Vienna, Austria; 11 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; and 12 Department of Cardiology, LKH, St Poelten, Austria
European Journal of Heart Failure, 2015 Dec;17(12):1252-1261
